Effectiveness of single-dose 6 mg pegfilgrastim in mobilizing peripheral blood stem cells in allogeneic hematopoietic cell transplantation donors.
Allogeneic donors
Pegfilgrastim
Recombinant human granulocyte colony-stimulating factor
Stem cell mobilization
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
01
08
2023
accepted:
18
09
2023
medline:
13
11
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
ppublish
Résumé
A single injection of 12 mg pegfilgrastim was used to mobilize peripheral blood progenitor cells (PBPCs) from healthy donors in some studies. The purpose of this study was to determine if 6 mg of pegfilgrastim was effective and safe for mobilizing CD34+ cells in donors for allogeneic hematopoietic stem cell transplantation. We conducted a retrospective case-matched design. A single dosage of 6 mg pegfilgrastim was used to mobilize PBPCs from 60 healthy donors. Granulocyte colony-stimulating factor (G-CSF, 10 μg/kg) was administered daily to the matched donors. Leukapheresis was scheduled to commence on day 4 of the mobilization regimen. The median yielded CD34+ cell in the pegfilgrastim group was higher than those in the G-CSF group, at 5.06 × 10
Identifiants
pubmed: 37773294
doi: 10.1007/s00277-023-05469-y
pii: 10.1007/s00277-023-05469-y
doi:
Substances chimiques
pegfilgrastim
3A58010674
Granulocyte Colony-Stimulating Factor
143011-72-7
Antigens, CD34
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3567-3573Subventions
Organisme : Ningbo Public welfare project
ID : 2019C50071
Organisme : Ningbo Social and Development project
ID : 2016C51018
Organisme : Yinzhou District Social and Development project
ID : YZ2017-59
Organisme : Zhejiang Medical Health Science and Technology Project
ID : 2023KY1143
Organisme : Ningbo Medical & Health Leading Academic Discipline Project
ID : 2022-S05
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Schmitz N, Dreger P, Suttorp M et al (1995) Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666–1672. https://doi.org/10.1182/blood.V85.6.1666
doi: 10.1182/blood.V85.6.1666
pubmed: 7534141
Kröger N, Zander AR (2002) Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma 43:1391–1394. https://doi.org/10.1080/10428190290033323
doi: 10.1080/10428190290033323
pubmed: 12389618
Curran MP, Goa KL (2002) Pegfilgrastim. Drugs 62:1207–1213; discussion 1214-5. https://doi.org/10.2165/00003495-200262080-00012
doi: 10.2165/00003495-200262080-00012
pubmed: 12010086
Bond TC, Szabo E, Gabriel S et al (2018) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract 24:412–423. https://doi.org/10.1177/1078155217714859
doi: 10.1177/1078155217714859
pubmed: 28614980
Link H, Thompson SF, Tian M et al (2022) A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany. Support Care Cancer 30:9317–9327. https://doi.org/10.1007/s00520-022-07353-3
doi: 10.1007/s00520-022-07353-3
pubmed: 36076105
Wang T, Feng R, Li JT et al (2021) Application of pegylated recombinant human granulocyte colony stimulating factor in mobilization of autologous peripheral blood stem cells. Zhonghua Xue Ye Xue Za Zhi 42:70–73. https://doi.org/10.3760/cma.j.issn.0253-2727.2021.01.014
doi: 10.3760/cma.j.issn.0253-2727.2021.01.014
pubmed: 33677872
Skopec B, Skerget M, Zontar D et al (2017) Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr 129:545–551. https://doi.org/10.1007/s00508-017-1205-z
doi: 10.1007/s00508-017-1205-z
pubmed: 28439700
Ding X, Huang W, Peng Y et al (2020) Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. Ann Hematol 99:1331–1339. https://doi.org/10.1007/s00277-019-03800-0
doi: 10.1007/s00277-019-03800-0
pubmed: 32382775
Hill GR, Morris ES, Fuery M et al (2006) Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 12:603–607. https://doi.org/10.1016/j.bbmt.2006.03.001
doi: 10.1016/j.bbmt.2006.03.001
pubmed: 16737933
Chanswangphuwana C, Kupatawintu P, Panjai P, Tunsittipun P, Intragumtornchai T, Bunworasate U (2014) Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation. Int J Hematol 99:18–22. https://doi.org/10.1007/s12185-014-1507-0
doi: 10.1007/s12185-014-1507-0
National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5.0.xlsx . NIH November 27, 2017
Wang K, Lv M, Chang YJ et al (2019) Early myeloid-derived suppressor cells (HLA-DR-/low CD33+ CD16-) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. J Hematol Oncol 12:31–46. https://doi.org/10.1186/s13045-019-0710-0
doi: 10.1186/s13045-019-0710-0
pubmed: 30885244
pmcid: 6423891
Biganzoli L, Untch M, Skacel T et al (2004) Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 31:27–34. https://doi.org/10.1053/j.seminoncol.2004.04.002
doi: 10.1053/j.seminoncol.2004.04.002
pubmed: 15181606
Kuan JW, Su AT, Wong SP et al (2015) A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization. Transfus Apher Sci 53:196–204. https://doi.org/10.1016/j.transci.2015.03.017
doi: 10.1016/j.transci.2015.03.017
pubmed: 25910537
Simona B, Cristina R (2010) Luca N, et al, A single dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. 43:321–326. https://doi.org/10.1016/j.transci.2010.10.001
Molineux G, Kinstler O, Briddell B et al (1999) A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724–1734. https://doi.org/10.1016/s0301-472x(99)00112-5
doi: 10.1016/s0301-472x(99)00112-5
pubmed: 10641590
Chanswangphuwana C, Kupatawintu P, Panjai P et al (2014) Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation. Int J Hematol 99:318–322. https://doi.org/10.1007/s12185-014-1507-0
doi: 10.1007/s12185-014-1507-0
pubmed: 24474639
Kroschinsky F, Hölig K, Poppe-Thiede K et al (2005) Single-dose pegfilgrastim for the mobilization of allogeneic CD34+peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 90:1665–1671. https://doi.org/10.1016/j.exphem.2005.08.003
doi: 10.1016/j.exphem.2005.08.003
pubmed: 16330441
Li JL, Wang SB, Zhang YC et al (2020) Is it better to mobilize hematopoietic stem cells with pegfilgrastim in healthy donors during allogeneic hematopoietic stem cell transplantation? Front Oncol 3:1598. https://doi.org/10.3389/fonc.2020.01598
doi: 10.3389/fonc.2020.01598
Bruns I, Steidl U, Kronenwett R et al (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:180–185. https://doi.org/10.1111/j.1537-2995.2006.00699.x
doi: 10.1111/j.1537-2995.2006.00699.x
pubmed: 16441592
Duong HK, Savani BN, Copelan E et al (2014) Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplan 20:1262–1273. https://doi.org/10.1016/j.bbmt.2014.05.003
doi: 10.1016/j.bbmt.2014.05.003
Huang XJ, Zhu HH, Chang YJ et al The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 119:5584–5590. https://doi.org/10.1182/blood-2011-11-389809